Curated News
By: NewsRamp Editorial Staff
June 11, 2025
Kamada Reports Stellar Q1 2025 Growth, Expands Plasma Operations
TLDR
- Kamada Ltd. reports a 17% revenue increase and 54% Adjusted EBITDA growth in Q1 2025, positioning it for organic growth and strategic acquisitions.
- Kamada's Q1 2025 revenue reached $44.0 million, driven by GLASSIA and KAMRAB sales, with gross margins up to 47% from 44% year-over-year.
- Kamada's advancements in treatments for AAT deficiency and rabies prevention, alongside plasma collection expansion, enhance global healthcare accessibility and disease management.
- Kamada launches a CMV research program and opens a new plasma center, aiming to innovate in disease prevention and treatment strategies.
Impact - Why it Matters
Kamada's impressive Q1 performance and strategic expansions underscore its potential in the biopharmaceutical sector, particularly in treatments for rare diseases and plasma-derived therapies. For investors and stakeholders, Kamada's growth trajectory and innovative research initiatives present a compelling case for its role in addressing unmet medical needs, while its expansion in plasma collection could enhance supply chain resilience and industry collaboration.
Summary
Kamada Ltd. (NASDAQ: KMDA) has reported a strong first quarter in 2025, with revenue up by 17% and Adjusted EBITDA by 54% year-over-year, signaling robust growth through its diverse portfolio and operational efficiency. CEO Amir London highlighted the company's disciplined expense management and portfolio diversity as key drivers. Notably, products like GLASSIA®, KAMRAB®, and VARIZIG® have contributed significantly to this growth, catering to treatments for emphysema, rabies prevention, and varicella disease prophylaxis, respectively. Kamada also launched a post-marketing research program for CYTOGAM®, aiming to enhance CMV disease management, and expanded its plasma collection operations with a new center in San Antonio, Texas, expected to add $8-$10 million in annual revenue. The company has reiterated its 2025 guidance, projecting total revenue between $178-$182 million and adjusted EBITDA of $38-$42 million, reflecting confidence in its strategic growth pillars.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Kamada Reports Stellar Q1 2025 Growth, Expands Plasma Operations
